Summary Loss of heterozygosity (LOH) was analysed in 84 primary tumours from sporadic, familial and hereditary breast cancer using five microsatellite markers spanning the chromosomal region 13ql2-ql3 which harbours the BRCA2 breast cancer susceptibility gene, and using one other marker located within the RBI tumour-suppressor gene at 13ql4. LOH at the BRCA2 region was found in 34% and at RBI in 27% of the tumours. Selective LOH at BRCA2 occurred in 7% of the tumours, whereas selective LOH at RBI was observed in another 7%. Moreover, a few tumours demonstrated a restricted deletion pattern, suggesting the presence of additional tumour-suppressor genes both proximal and distal of BRCA2. LOH at BRCA2 was significantly correlated to high S-phase values, low oestrogen and progesterone receptor content and DNA non-diploidy. LOH at BRCA2 was also associated, albeit non-significantly, with large tumour size and the ductal and medullar histological types. No correlation was found with lymph node status, patient age or a family history of breast cancer. A highly significant and independent correlation existed between LOH at BRCA2 and early recurrence and death. LOH at RBI was not associated with the above mentioned factors or prognosis. The present study does not provide conclusive evidence that BRCA2 is the sole target for deletions at 13ql2-ql3 in breast tumours. However, the results suggest that inactivation of one or several tumoursuppressor genes in the 13q12 -q 13 region confer a strong tumour growth potential and poor prognosis in both familial and sporadic breast cancer.
The study of hereditary cancer syndromes and identification of mutated predisposing genes has provided clues to the initial genetic events in carcinogenesis, some of which may also be involved in sporadic forms of the diseases (Knudsen, 1993) . This model may also be used in elucidating the multifactorial cause of breast cancer, a disease in which genetic components have been implicated but in which precursor lesions are hard to define and analyse.
A major breast and ovarian cancer susceptibility gene, BRCAI on chromosome 17q21, has been identified by positional cloning . The frequent finding of putative loss-of-function germline mutations in breast/ ovarian cancer families and the loss of the wildtype allele in corresponding tumours suggests that BRCA1 is a tumoursuppressor gene inactivated by classical mechanisms. However, although loss of heterozygosity (LOH) of the 17q21 region and a reduced BRCAJ expression is observed in invasive sporadic breast cancer (Thompson et al., 1995) , somatic BRCA1 mutations are infrequent in breast and ovarian tumours Merajver et al., 1995) , suggesting that the role of BRCAI in tumorigenesis may be restricted to the hereditary form of the disease.
A second major breast cancer susceptibility gene, BRCA2, was recently identified at chromosome 13ql2, proximal to the retinoblastoma (RB]) gene at 13ql4 (Wooster et al., 1995; Tavtigian et al., 1996) . The findings of frequent LOH at chromosome 13q in breast cancer (Varley et al., 1989) have previously been assumed to be owing to the involvement of the RB] gene in tumour development. However, in an earlier study , we found an incomplete correlation between LOH and loss of RBI expression, suggesting that other adjacent genes might also be targets for deletions. This presumption was subsequently reinforced by the isolation of Brush-], a gene proximal to RB1 on 13ql2-ql3 which manifests reduced expression in tumours with LOH (Schott et al., 1994 Time to recurrence (years) Figure 2 Disease-free survival in 83 breast cancers categorised after LOH at the BRCA2 locus (a) and in 60 breast cancers categorised after LOH at the RBI gene (b). (P=0.0041). This correlation was less evident for cases with LOH at RBI; in fact none of the six patients with tumours manifesting LOH limited to RBI had recurring disease or had died. However, the worst prognosis was found in the group of cases with LOH at both BRCA2 and RBI, more than half (11 of 20) of which had recurring disease within the median follow-up period of 38 months, compared with one of six patients with LOH solely at BRCA2. LOH at chromosome 16q was not related to either shortened disease-free or overall survival.
Multivariate disease-free survival analyses were also performed, including as covariates LOH at BRCA2, lymph node status, tumour size, age, ER and PgR status. LOH at BRCA2 was found to be an independent prognostic factor (Table II) .
Discussion
Allelic deletion and loss of heterozygosity constitutes the second event in the genetic two-hit model, according to which both copies of a tumour-suppressor gene are inactivated (Knudsen et al., 1993) . Consequently, the findings of a high frequency of LOH at the BRCAI breast cancer susceptibility gene on chromosome 17q21 both in hereditary and sporadic breast tumours are strongly suggestive of a general involvement of this putative tumour-suppressor gene in breast tumorigenesis. However, while the unmasking of a recessive BRCA] mutation by deletion of the remaining wildtype allele holds to be true in hereditary BRCAI-linked tumours (Smith et al., 1992; Johannsson et al., 1996) , the evidence for the importance of BRCA] in sporadic breast cancer with LOH on 17q21 is still controversial .
The objective of the present study was to investigate the involvement of the chromosomal region 13ql2-ql4, comprising the BRCA2 and RB] loci, and its possible clinical importance in breast cancer. In accordance with the findings at BRCAI, a similarly high frequency (>30%) of LOH was found at BRCA2 in sporadic, familial and hereditary tumours. Moreover, not only was the frequency of LOH lower at RB], but the relationship to aggressive tumour phenotype (high proliferation, autonomous growth, genetic instability, etc.) and poor prognosis was more or less confined to tumours manifesting allelic loss at BRCA2, with or without concomitant loss of RB]. This implies that BRCA2, or an additional adjacent gene other than RB], is the likely target for 13q deletions in breast cancer, in keeping with our earlier observations of a lack of association between LOH at RB] and loss of pRB expression .
Strong evidence for the inactivation of BRCA2 via the postulated two-hit mechanism was recently provided in studies of breast cancer and other tumours from disease haplotype carriers of a BRCA2-linked family, demonstrating a preferential loss of the wild type allele Gudmundsson et al., 1995 RBI (Schott et al., 1994) . The presence of at least three tumour-suppressor genes in the 13ql2-ql4 region may explain why extensive deletions, or even the loss of a whole chromosome 13, are common and selected for in breast cancer (Devilee et al., 1989) . One previous investigation of sporadic breast cancer and alterations in the 13ql2-ql4 region demonstrated allelic loss in 32% of 200 tumours and a simultaneous loss of both the BRCA2 and RBI loci in all cases (Cleton-Jansen et al., 1995) , whereas another report has pointed out the restricted involvement of the BRCA2 loci in some tumours (Kerangueven et al., 1995) .
The finding of the near complete loss of one allele (merely a faint band visible, presumably representing DNA from normal tissue within the tumour) in a considerable proportion of tumours suggests that 13q deletion is an early step in tumour development. Additionally, loss of a 13ql2-q14 gene may confer a strong growth advantage to the cell, resulting in a selective outgrowth of cell clones which harbour the losses. Furthermore, the strong correlation between LOH and high S-phase fraction values indicates the inactivation of a gene (or several genes) involved in cell cycle control. It is unlikely that these associations are due to a general genomic instability, as there was no correlation between LOH at chromosome 13q and 16q, and as the latter alteration was unrelated to prognosis. However, the present study provides no proof that the association with aggressive tumour behaviour is specifically as a result of inactivation of the BRCA2 gene. Certainly, in a parallel study of biological tumour features from individuals with germline BRCA] mutations or manifesting clear BRCA] linkage, a relationship to aggressive phenotype and rapid proliferation has been noted (Johannsson et al., submitted) . This implies that a functional similarity between these breast cancer susceptibility genes may exist and that their inactivation initiates a dedifferentiated state and a certain genetic pathway, leading to rapid tumour progression. Although we have seen only a tendency towards a worse prognosis in BRCAI-induced breast cancer (Johannsson et al., submitted) , LOH at the chromosomal region comprising the BRCA2 gene was strongly and independently correlated to early recurrence and death. This association was evident in both familial and hereditary tumours as well as in sporadic tumours, suggesting that alterations of the putative target gene constitutes a new prognostic factor of potential clinical importance.
